研究显示,在结合提尔泽帕提德和激素治疗后,更肥胖的女性体重减轻. Study shows postmenopausal obese women lost more weight combining tirzepatide with hormone therapy.

在ENDO 2025年提交的一项研究显示,肥胖后绝经期妇女将肥胖药物tirzepatide与更年期激素治疗相结合,与仅使用tirzepatide相比,体重下降幅度更大。 A study presented at ENDO 2025 showed that postmenopausal women with obesity lost more weight when combining obesity medication tirzepatide with menopause hormone therapy compared to using tirzepatide alone. 合并导致体重下降17%,而仅tirzepatide就下降了14%,这表明对绝经后的妇女来说,体重管理选择更为有效。 The combination led to a 17% weight loss, compared to 14% with tirzepatide alone, suggesting a more effective weight management option for postmenopausal women. 需要进一步的研究,以了解治疗方法之间的相互作用。 Further research is needed to understand the interaction between the treatments.